Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation.
Tacrine (THA), used in the treatment of Alzheimer's disease, is known to induce hepatotoxicity, the mechanisms of which remain to be fully established. We have previously shown that THA reduced intracellular glutathione concentration in rat hepatocytes in primary culture, thus pointing to a possible role for oxidative stress in THA toxicity. To test this, the effects of antioxidant molecules, namely, the flavonoids silibinin, silibinin dihydrogensuccinate, and silymarin, were evaluated on the toxicity of THA in cultured rat hepatocytes. This toxicity was investigated after a 24-h treatment over a concentration range from 0 to 1 mM, in the presence or absence of antioxidant (1 and 10 microM). We found that simultaneous treatment of hepatocytes with any of the antioxidants and THA remained ineffective on the lactate dehydrogenase release induced by THA. Then, the production of lipid-derived radicals (to estimate lipid peroxidation) was measured in THA (0.05-0.50 mM)-treated cells using a spin-trapping technique coupled to electron paramagnetic resonance (EPR) spectroscopy. No increase of the EPR signal was observed over the period of 30 min to 24 h. In contrast, treatment of cells with the spin label 12-doxyl stearic acid followed by EPR spectroscopy showed that THA (0.05 and 0.25 mM) rapidly increased hepatocyte membrane fluidity. Extracellular application of GM1 ganglioside (60 microM) both reversed this increase in fluidity and partially reduced lactate dehydrogenase release on THA exposure. In conclusion, this work indicates that early alterations of membrane fluidity, not resulting from lipid peroxidation, are likely to play an important role in the development of THA toxicity.
Galisteo
M
M
Institut National de la Sant¿e et de la Recherche M¿edicale U456, D¿etoxication et R¿eparation Tissulaire, Facult¿e des Sciences Pharmaceutiques et Biologiques, Universit¿e de Rennes I, Rennes, France.
Rissel
M
M
Sergent
O
O
Chevanne
M
M
Cillard
J
J
Guillouzo
A
A
Lagadic-Gossmann
D
D
D000818:Animals; D002478:Cells, Cultured; D002800:Cholinesterase Inhibitors / Q000633:toxicity*; D004578:Electron Spin Resonance Spectroscopy; D005677:G(M1) Ganglioside / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D008099:Liver / Q000187:drug effects*; D008297:Male; D008560:Membrane Fluidity / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012838:Silymarin / Q000494:pharmacology; D013619:Tacrine / Q000633:toxicity*
D002800:Cholinesterase Inhibitors; D012838:Silymarin; D005677:G(M1) Ganglioside; D013619:Tacrine; D007770:L-Lactate Dehydrogenase